동아에스티 '모티리톤', 소화불량 넘어 편두통까지 잡는다

Motilitone's sustained market leadership over 15 years demonstrates the competitive advantage of multi-mechanism drugs backed by rigorous clinical research. Recent findings showing efficacy in migraine-associated nausea and headache reduction highlight how established gastrointestinal medications can successfully expand into adjacent therapeutic areas, offering patients broader treatment options beyond their original indication.